Enzymatic extract from Ecklonia cava: Acute and subchronic oral toxicity and genotoxicity studies
| Autor: | Euna Kwon, Jin-Sung Park, In Jue Yun, Eun Young Cho, Je Hun Oh, Yun Soon Kim, Ja June Jang, Jun Won Yun, Jeong Hwan Che, Jung Hee Yoon, Byeong Cheol Kang, Ji Ran You, Seung Hyun Kim |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Male Ecklonia cava No-observed-adverse-effect level Administration Oral Pharmacology Toxicology medicine.disease_cause Chromosome aberration Ames test Rats Sprague-Dawley 03 medical and health sciences Mice 0302 clinical medicine Dogs medicine Toxicity Tests Acute Animals Mice Inbred ICR No-Observed-Adverse-Effect Level biology Chemistry Mutagenicity Tests Plant Extracts Toxicity Tests Subchronic General Medicine Organ Size biology.organism_classification Acute toxicity Rats 030104 developmental biology 030220 oncology & carcinogenesis Micronucleus test Toxicity Female Laminaria Genotoxicity |
| Zdroj: | Regulatory toxicology and pharmacology : RTP. 92 |
| ISSN: | 1096-0295 |
| Popis: | Ecklonia cava (EC) is known to have antioxidant, anti-inflammatory, antidiabetic, and anticancer properties. Despite its wide use and beneficial properties, comprehensive toxicological information regarding EC extract is currently limited. Therefore, the purpose of this study was to investigate acute toxicity, subchronic toxicity, and genotoxicity of enzymatic EC extract according to test guidelines published by Organization for Economic Cooperation and Development. The acute oral LD50 values of this EC extract administered to rats and dogs were estimated to be more than 3000 mg/kg BW. In an oral 13-week toxicity study, changes in body weights of rats exposed to the EC extract up to 3000 mg/kg BW were found to be normal. In addition, repeated doses of EC extract failed to influence any systematic parameters of treatment-related toxic symptoms such as food/water consumption, mortality, urinalysis, hematology, serum biochemistry, organ weight, or histopathology. These results indicated that the no-observed-adverse-effect level for the EC extract was 3000 mg/kg/day for male and female rats. Data obtained from Ames test, chromosome aberration assay, and micronucleus assay indicated that EC extract was not mutagenic or clastogenic. Taken together, these results support the safety of enzymatic EC extract as a potential therapeutic for human consumption against various diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect